Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Phase 3
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT00060476
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
- Detailed Description
The duration of treatment is 6 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 15000
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time to prostate cancer Duration of Treatment
- Secondary Outcome Measures
Name Time Method Time to aggressive prostate cancer Duration of Treatment